SCIEX Triple Quad 6500+ Liquid Chromatography Tandem Quadrupole Mass Spectrometer

Overview

The SCIEX Triple Quad 6500+ is a high-performance liquid chromatography–tandem quadrupole mass spectrometry (LC-MS/MS) system engineered for ultra-sensitive, high-throughput quantitative analysis in regulated and research environments. Built upon the patented IonDrive™ technology platform, it integrates three core innovations—IonDrive Turbo V ion source, IonDrive QJet ion guide, and IonDrive High-Energy Detector+—to maximize ion generation, transmission efficiency, and detection sensitivity across both positive and negative electrospray ionization (ESI) modes. The system operates on collision-induced dissociation (CID) principles within a triple quadrupole architecture, enabling robust multiple reaction monitoring (MRM) acquisition with exceptional specificity and reproducibility. With a mass range extending to 2000 m/z and scan speeds up to 12,000 Da/sec, the 6500+ supports ultra-high-performance liquid chromatography (UHPLC) methods without sacrificing dwell time or data point density per peak. Its design meets the analytical demands of complex biological matrices, environmental extracts, food homogenates, and forensic specimens—particularly where low-level quantitation, wide dynamic range, and rapid polarity switching are critical.

Key Features

• IonDrive Turbo V ion source with optimized gas dynamics and heater configuration for enhanced ionization efficiency across flow rates from 5 µL/min to 3 mL/min—compatible with microbore, analytical, and UHPLC columns.
• Patented IonDrive QJet ion guide featuring dual-stage geometry: a larger first-stage radius for increased ion capture capacity and a narrower second-stage aperture for improved focusing into Q0, resulting in higher ion transmission efficiency.
• IonDrive High-Energy Detector+ with floating high-voltage architecture, delivering extended linear dynamic range (>6 orders), sub-picomolar detection limits, and sub-5-ms polarity switching without signal loss or recalibration.
• Native compatibility with SelexION+ differential mobility spectrometry for orthogonal gas-phase separation—enhancing selectivity in co-eluting analytes while maintaining quantitative integrity and LOQ performance.
• MRM Pro algorithm embedded in Analyst® software for intelligent, automated MRM transition scheduling—enabling >600 transitions per injection with full retention time alignment and peak integration fidelity.
• Acoustically damped enclosure design reducing operational noise to <55 dB(A), supporting integration into shared laboratory spaces without acoustic interference.

Sample Compatibility & Compliance

The Triple Quad 6500+ accommodates diverse sample types—including plasma, serum, tissue homogenates, urine, soil extracts, food digests, and surface swabs—without requiring extensive method re-optimization. Its broad mass range (up to 2000 m/z) supports analysis of large peptides, oligonucleotides, and adducted metabolites alongside small molecules. The system complies with international regulatory frameworks including FDA 21 CFR Part 11 (with audit trail, electronic signature, and role-based access control enabled via Analyst® software), ISO/IEC 17025 requirements for testing laboratories, and ICH M10 guidelines for bioanalytical method validation. Routine performance verification follows SCIEX-defined QC protocols aligned with ASTM D7894 and USP for method suitability assessment.

Software & Data Management

Controlled exclusively through SCIEX OS and Analyst® 1.7.2 or later, the system supports fully traceable data acquisition, processing, and reporting workflows. Analyst® includes integrated tools for MRM optimization, calibration curve fitting (weighted 1/x² regression), matrix effect evaluation, and carryover assessment—all compliant with GLP/GMP documentation standards. Raw data files (.wiff) are stored in vendor-neutral formats compatible with third-party platforms such as SimGlycan®, Compound Discoverer™, and OpenMS. Audit trails record all user actions—including parameter changes, sequence edits, and report generation—with immutable timestamps and operator identification. Data integrity safeguards include automatic backup, checksum validation, and optional integration with enterprise LIMS systems via ODBC or RESTful API.

Applications

• Bioanalysis: Quantification of small-molecule drugs, large-molecule biologics (e.g., monoclonal antibodies via surrogate peptide approaches), and endogenous biomarkers in plasma and CSF under FDA/EMA bioanalytical guidance.
• Food safety: Multi-residue screening of pesticides, veterinary drug residues, mycotoxins, and environmental contaminants (e.g., PFAS) at EU-MRL and FDA Action Level thresholds.
• Environmental monitoring: Trace-level detection of pharmaceuticals, flame retardants, plasticizers, and persistent organic pollutants (POPs) in wastewater, sediment, and biota.
• Clinical toxicology: High-sensitivity, multi-analyte panels for forensic drug screening—including opioids, benzodiazepines, synthetic cannabinoids, and novel psychoactive substances—in whole blood and oral fluid.
• Pharmaceutical development: Impurity profiling, degradation product identification, and extractables/leachables analysis per ICH Q5A(R2) and Q3E guidelines.

FAQ

What ionization sources are supported on the Triple Quad 6500+?
The system natively supports IonDrive Turbo V, TurboIonSpray, APCI, DuoSpray, PhotoSpray, NanoSpray III, Phytronix LDTD, Advion LESA Clarity, and Digital PicoView sources—all interchangeable without hardware modification.
Is SelexION+ differential mobility integration mandatory?
No—SelexION+ is an optional module. The base Triple Quad 6500+ delivers full QqQ performance without it; SelexION+ adds orthogonal selectivity for challenging isobaric interferences.
Does the system meet FDA 21 CFR Part 11 requirements?
Yes—when configured with Analyst® software v1.7.2+, enabled audit trail, electronic signatures, and secure user authentication, it satisfies Part 11 compliance for regulated submissions.
What is the typical LLOQ achievable for small molecules in plasma?
Under optimized conditions (e.g., protein precipitation + UHPLC separation), sub-1 pg/mL LLOQs are routinely achieved for many analytes—validated per ICH M10 and EMA bioanalytical guidelines.
Can the detector operate simultaneously in positive and negative mode?
No—the detector switches polarity in <5 ms, but acquisition is sequential per cycle; however, MRM Pro scheduling ensures comprehensive coverage of both polarities within a single injection.